 |
|
|
| |
Interim Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABI-H0731, a Novel Core Protein Allosteric Modifier (CpAM),
in Healthy Volunteers and Non-Cirrhotic Viremic Subjects with Chronic Hepatitis B
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Late Breaker poster
Download the PDF here
MF Yuen1, K Agarwal2, EJ Gane3, C Schwabe3, SH Ahn4, DJ Kim5, YS Lim6, W Cheng7, W Sievert8, K Visvanathan9, E Ruby10, S Liaw10, R Colonno10and U Lopatin10
1Queen Mary Hospital, Hong Kong; 2Kings College Hospital, London, United Kingdom; 3Auckland Clinical Studies, Auckland, New Zealand; 4Severance Hospital, Seoul, Republic of Korea; 5Hallym University, ChuncheonSacred Heart Hospital, Gangwon-do, Republic of Korea;
6Asan Medical Center, Seoul, Republic of Korea; 7Linear Clinical Research, Perth, Australia; 8Monash Health, Victoria, Australia; 9St. Vincent's Hospital, Victoria, Australia; 10Assembly Biosciences, Inc., San Francisco, California, USA
|
| |
|
|
|
|
|
